NYSE · Healthcare · Drug Manufacturers - General
Latest call day: 2026-08-25 · full consensus board · graded history
Price (daily close, 2026-08-24)
Today's calls AI
| Pharma & Managed Care · MACD | DOWN 75% | MACD — MACD histogram momentum crossover. ABBV ranks #8 of 13 in Pharma & Managed Care (75% bearish percentile), so the agent calls it DOWN for the next session. |
| Pharma & Managed Care · Quality | UP 75% | Quality — operating margin plus revenue growth. ABBV ranks #4 of 13 in Pharma & Managed Care (75% bullish percentile), so the agent calls it UP for the next session. |
| Pharma & Managed Care · RSI Mean-Reversion | DOWN 75% | RSI Mean-Reversion — oversold up / overbought down. ABBV ranks #8 of 13 in Pharma & Managed Care (75% bearish percentile, RSI 76), so the agent calls it DOWN for the next session. |
| Pharma & Managed Care · Long-Term Reversal | UP 67% | Long-Term Reversal — year-long losers rebound. ABBV ranks #5 of 13 in Pharma & Managed Care (67% bullish percentile, signal -30.2%), so the agent calls it UP for the next session. |
Best agents on ABBV (graded record)
| Pharma & Managed Care · Quality | 70% | 7/10 correct | UP |
| Pharma & Managed Care · Meta-Ensemble | 69% | 9/13 correct | UP |
| Pharma & Managed Care · RSI Mean-Reversion | 65% | 15/23 correct | DOWN |
| Pharma & Managed Care · Breakout | 65% | 13/20 correct | DOWN |
| 3-Month Momentum | 60% | 3/5 correct | UP |
| Pharma & Managed Care · Momentum Acceleration | 56% | 9/16 correct | DOWN |
| Pharma & Managed Care · Trend Strength | 53% | 16/30 correct | UP |
| Pharma & Managed Care · Bollinger Reversion | 52% | 12/23 correct | UP |
| Pharma & Managed Care · Volume Thrust | 52% | 14/27 correct | DOWN |
| Pharma & Managed Care · OBV Trend | 50% | 16/32 correct | DOWN |
Recent news
| 2026-08-25 | Judge Allows Hospital Groups To Fight AbbVie 340B Suit - Law360 · Law360 |
| 2026-08-25 | How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds? · yf_tkr_MRK |
| 2026-08-25 | Is AbbVie (ABBV) Quietly Rebalancing Its Growth Story Around Oncology Innovation? · yf_tkr_ABBV |
| 2026-08-24 | The Multibillion-Dollar Molecule: How Zumilokibart’s Phase 2 Success Sparked AbbVie’s Acquisition - Dermatology Times · Dermatology Times |
| 2026-08-24 | AbbVie Still Has Room To Run · seeking_alpha |
| 2026-08-24 | J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead · yf_tkr_ABBV |
How grading works: every call is locked before the open and scored on the session's open→close move — see the methodology.
Open Fortivio.AI →Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。